GET A PIECE OF VITA IMAGING
Vita Imaging believes its technology sets a new standard in early and accurate detection of skin cancer
*AURA™ IS PRE-FDA APPROVAL AND NOT YET AVAILABLE. PLEASE SEE THE OFFERING MEMORANDUM’S COMPANY OVERVIEW SECTION FOR INFORMATION REGARDING THE COMPANY’S IP LICENSING AGREEMENTS.
Hear what Kevin O’Leary thinks about Vita Imaging
Watch the 5-minute Pitch + Q&A
Reasons to Invest
Vita Imaging’s AURA™ diagnostic device can detect skin cancer in two seconds, reducing biopsies and optimizing treatment. AURA™ is already in the FDA clearance process, with approval expected in the second half of 2025.
Skin cancer is the most common cancer in the U.S., with 1/5 Americans developing it in their lifetime & about 9.5K new cases daily. The Global Cancer Diagnostics Market is expected to reach $204.8 billion by 2032.
The company’s CEO is a Stanford engineering grad, and has previously taken a high-tech startup public on NASDAQ, reaching a market cap of $2B+ in 2007, before leaving in 2018.
Turning Subjective Medical Decisions Into Objective Diagnostics, In Seconds
*AURA™ is currently undergoing FDA review and is not yet approved for use.
The Problem & Our Solution
5.4 million people are treated for skin cancer yearly.
But current methods for detecting skin cancer are costly, inefficient, and subjective.
That’s why Vita Imaging created AURA: a first-of-its-kind, non-invasive Raman spectroscopy device candidate that can identify benign and malignant lesions in less than 2 seconds. The AURA is currently advancing toward FDA market clearance and preparing for commercial launch after successful testing in comprehensive clinical studies.
The AURA product is pre-FDA approval and is not yet available in the market.
The AURA is so easy it can be operated in just three, non-invasive steps, meaning it can quickly be deployed in any dermatological clinic or healthcare facility.
Power up the AURA Imaging Device
Scan the Affected Area Using the Light Probe Instant Result (2 seconds)
Review Display for Recommendation & Recommended Next Steps
AURA Development – Past to Present
After $20 million of investment and countless hours of design, engineering, and testing, the AURA™ was created.
To-date, AURA™ has been tested in comprehensive clinical studies – including the largest known study using Raman technology for skin cancer detection – and has successfully passed all product performance and safety tests. Therefore, we believe that AURA™ has strong potential to exceed FDA benchmarks, potentially paving the way for future clearance and commercialization as a Class III medical device, subject to FDA review.
Sir CV raman’s original system (1928)
Rapid raman system built at the bc cancer agency (2002)
Beta test version
First generation commercial product (2012)
VITA IMAGING’S AURA (2023)
The AURA product is pre-FDA approval and is not yet available in the market.
To our knowledge, this would make AURA™ the first device of its kind to receive FDA clearance, potentially paving the way for broader market adoption.
AURA Development – Past to Present
After $20 million of investment and countless hours of design, engineering, and testing, the AURA™ was created.
To-date, AURA™ has been tested in comprehensive clinical studies – including the largest known study using Raman technology for skin cancer detection – and has successfully passed all product performance and safety tests. Therefore, we believe that AURA™ has strong potential to exceed FDA benchmarks, ideally paving the way for full clearance and commercialization as a Class 3 medical device.
Sir CV raman’s original system (1928)
Rapid raman system built at the bc cancer agency (2002)
Beta test version
First generation commercial product (2012)
VITA IMAGING’S AURA (2023)
The AURA product is pre-FDA approval and is not yet available in the market.
This would make the AURA the first approved device of its kind on the market, paving the way for mass adoption in the market.
What Sets Aura Apart from Existing Devices
A high-quality skin cancer detection device requires two properties to be successful:
While other medical device companies tout their skin cancer diagnostic devices, no product currently on the market matches the AURA’s sensitivity, specificity and testing time in a non-invasive device.
Preliminary data. Aura is not FDA-cleared. Comparisons reflect varying study methods and populations. See offering for details.
Why Invest
A Strong Business Model
Vita Imaging has a quality business model plan ready that is expected to provide the company with solid cash flow from both device sales, recurring revenue, and potential future business opportunities.
Vita Imaging Roadmap
We already have exciting plans for the coming years, including:
Featured On
Our Team
Thinh Tran • CEO & Chairman
Mr. Tran was the Founder, CEO, & Chairman of V-Silicon, a leader in the Smart TV market delivering best in class picture and audio quality. He was previously the Founder, Chairman, & CEO of Sigma Designs since its inception in 1982 which he built from a humble start-up a publicly traded NASDAQ company, at one point was valued at two billion dollars in 2007, before leaving in 2018.
Victoria ReadeCOO
Ms. Reade has 25+ years of executive leadership and consulting experience including: Executive Director, MCO Operations & MSO at Scripps Clinic & Green Hospital La Jolla; VP, Medical Management at HMO Pacificare, Healthcare/IT Consultant at Deloitte, TMI, Pharma & Medtech.
Dzung Kim Tran WrightCFO
Ms. Wright is the Chief Financial Officer of Vita Imaging, Inc. She has over 30 years of experience in the financial industry, holding senior financial positions at multiple publicly traded and startup companies over a wide range of industries such as medical, telecommunications, device technology, digital arts, mobile devices, and internet technology.
Invest in a Company That’s Doing Good For the World
Invest in a Company That’s Doing Good For the World
Join us and help us create a new standard in medical diagnostics.
Join us and help us create a new standard in medical diagnostics.
The AURA product is pre-FDA approval and is not yet available in the market.
What Is Equity Crowdfunding?
Equity crowdfunding lets everyday people invest in private companies—like startups or small businesses—and become part-owners.
- You invest money in a private company (not on the stock market)
- You get shares in the company (called “equity”)
- If the company grows, your shares may become more valuable
- If the company fails, you could lose your investment
- Not listed on the stock market (like Apple or Google)
- Usually early-stage or growing businesses
- You’re investing early—before most people can
- You invest online through regulated platforms like StartEngine or Wefunder
- These are long-term investments (you might not see returns quickly)
- Always read the company’s fundraising page and disclosures
- You can lose money—only invest what you can afford